ATE373640T1 - Optische auflösung von methylphenidat mittels 0, 0'-bisaroyl-weinsäuren - Google Patents

Optische auflösung von methylphenidat mittels 0, 0'-bisaroyl-weinsäuren

Info

Publication number
ATE373640T1
ATE373640T1 AT97901158T AT97901158T ATE373640T1 AT E373640 T1 ATE373640 T1 AT E373640T1 AT 97901158 T AT97901158 T AT 97901158T AT 97901158 T AT97901158 T AT 97901158T AT E373640 T1 ATE373640 T1 AT E373640T1
Authority
AT
Austria
Prior art keywords
methylphenidate
bisaroyl
tartar
acids
optical resolution
Prior art date
Application number
AT97901158T
Other languages
English (en)
Inventor
Michael Harris
Hooshang Zavareh
Original Assignee
Celltech Pharma Europ Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9601228.1A external-priority patent/GB9601228D0/en
Application filed by Celltech Pharma Europ Ltd filed Critical Celltech Pharma Europ Ltd
Application granted granted Critical
Publication of ATE373640T1 publication Critical patent/ATE373640T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0004—Crystallisation cooling by heat exchange
    • B01D9/0013—Crystallisation cooling by heat exchange by indirect heat exchange

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Thermal Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT97901158T 1996-01-22 1997-01-22 Optische auflösung von methylphenidat mittels 0, 0'-bisaroyl-weinsäuren ATE373640T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9601228.1A GB9601228D0 (en) 1996-01-22 1996-01-22 Resolution
GB9700156 1997-01-20

Publications (1)

Publication Number Publication Date
ATE373640T1 true ATE373640T1 (de) 2007-10-15

Family

ID=26308503

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97901158T ATE373640T1 (de) 1996-01-22 1997-01-22 Optische auflösung von methylphenidat mittels 0, 0'-bisaroyl-weinsäuren

Country Status (12)

Country Link
EP (1) EP0883608B1 (de)
JP (1) JP4163748B2 (de)
KR (1) KR19990081891A (de)
AT (1) ATE373640T1 (de)
AU (1) AU716570B2 (de)
CA (1) CA2242595A1 (de)
CZ (1) CZ225198A3 (de)
DE (1) DE69738154T2 (de)
HU (1) HUP9900798A3 (de)
MX (1) MX9805870A (de)
SK (1) SK98098A3 (de)
WO (1) WO1997027176A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486177B2 (en) 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
JP2000504008A (ja) * 1996-02-02 2000-04-04 メデバ・ユアラプ・リミテッド Ｄ―トレオ―（ｒ，ｒ）―メチルフェニデートの調製およびエピメリゼーションによる不要エナンチオマーリサイクルの方法
US6100401A (en) * 1998-04-20 2000-08-08 Novartris Ag Process for preparing the d-threo isomer of methylphenidate hydrochloride
US6162919A (en) * 1998-12-03 2000-12-19 Novartis Ag Process for preparing the d-threo isomer of methylphenidate hydrochloride
US6025502A (en) * 1999-03-19 2000-02-15 The Trustees Of The University Of Pennsylvania Enantopselective synthesis of methyl phenidate
GB9913458D0 (en) * 1999-06-09 1999-08-11 Medeva Europ Ltd The therapeutic use of d-threo-methylphenidate
WO2001043730A2 (en) * 1999-12-17 2001-06-21 Medeva Europe Limited The treatment of convulsive states
AU2002353803A1 (en) * 2001-10-12 2003-04-22 Sention, Inc. Direct resolution of racemic threo-methylphenidate hydrochloride
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
US7229557B2 (en) 2004-02-04 2007-06-12 Konec, Inc. Method to separate stereoisomers
US7897777B2 (en) * 2007-01-05 2011-03-01 Archimica, Inc. Process of enantiomeric resolution of D,L-(±)-threo-methylphenidate
US8552030B2 (en) 2009-05-07 2013-10-08 Malladi Drugs & Pharmaceuticals Ltd. Process for the preparation of d-threo-ritalinic acid hydrochloride by resolution of dl-threo-ritalinic acid using chiral carboxylic acid
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
WO2012129551A1 (en) 2011-03-23 2012-09-27 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2957880A (en) * 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
JPH07247286A (ja) * 1994-01-18 1995-09-26 Sankyo Co Ltd 含窒素環状化合物の光学分割方法
MX9605611A (es) * 1994-05-16 1998-05-31 Merrell Pharma Inc Procedimiento y sales diastereomericas utiles para la resolucion optica de a-(4-(1,1-dimetiletil)fenil)-4-(hidroxidifenil-metil)-1-pipe ridinbutanol racemico y compuestos derivados.

Also Published As

Publication number Publication date
EP0883608B1 (de) 2007-09-19
AU716570B2 (en) 2000-03-02
SK98098A3 (en) 1999-03-12
MX9805870A (de) 1999-01-31
CA2242595A1 (en) 1997-07-31
DE69738154D1 (de) 2007-10-31
HUP9900798A3 (en) 1999-11-29
DE69738154T2 (de) 2008-06-12
KR19990081891A (ko) 1999-11-15
EP0883608A1 (de) 1998-12-16
HUP9900798A2 (hu) 1999-07-28
AU1450397A (en) 1997-08-20
JP4163748B2 (ja) 2008-10-08
JP2000517288A (ja) 2000-12-26
CZ225198A3 (cs) 1998-12-16
WO1997027176A1 (en) 1997-07-31

Similar Documents

Publication Publication Date Title
ATE373640T1 (de) Optische auflösung von methylphenidat mittels 0, 0'-bisaroyl-weinsäuren
ATE130604T1 (de) Neue arylethylaminderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ATE312073T1 (de) Sustiuierte cyclische verbindungen, verfahren zu ihrer herstellung sowie sie enthaltende pharmazeutische zusammesetzungen
NO20071498L (no) Substituerte acylhydroksamsyrer samt fremgangsmate for a redusere TNFa-nivaet
MX9203346A (es) (+)-1-(3-dimetilaminopropil)-1-(4'-fluorfenil)-1,3-dihidro-sobenofuran -5-carbonitrilo y sus sales de adicion de acido no toxicas farmaceuticamente utiles.
PT93246A (pt) Processo para a preparacao de compostos pirrolicos substituidos e de composicoes farmaceuticas que os contem
EA199800357A1 (ru) Фармацевтические ангиостатические дипептидные композиции и способы их применения
ATE266671T1 (de) Nukleinsäuresynthese unter verwendung von mittels licht abspaltbaren schutzgruppen
ATE156818T1 (de) Polyfluoralkylthiopoly(ethylimidazolium)- verbindungen, verfahren zu ihrer herstellung und ihre verwendung als biozide mittel
DE68911834D1 (de) Verfahren zur Herstellung von 7-substituierten Hept-6-en- und Heptansäuren und Derivaten davon.
UA26431A (uk) Похідhі сиh-ізомеру цефалоспориhу, їх оптичhо активhі аhтиподи або рацемічhа суміш, а також їх фармацевтичhо прийhятhі кислотhо-адитивhі солі
DE69207429D1 (de) Verfahren zur herstellung von substituierten piperidinen
ATE144498T1 (de) Herstellung von substituierten piperidinen
DE69433012D1 (de) Verfahren zur herstellung von oralen dosierungsformulierungen enthaltend diclofenac
RU94038042A (ru) Производные гексагидроазепинов, фармацевтическая композиция на их основе и антипсихотропный агент
DE69613395D1 (de) Schwefelenthaltende di-ter-butylphenol-verbindungen brauchbar als entzündungshemmende mittel
FI881609A (fi) Dihydropyridinamider, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.
ATE71388T1 (de) Sofort vernetzbare zusammensetzung.
ES433860A1 (es) Procedimiento de preparacion de derivados del acido ciclo- pentano-carboxilico.
ES2076616T3 (es) Derivados de aminoacidos sulfurosos opticamente activos, su preparacion, su polimerizacion en polimeros opticamente activos y su uso.
ATE199909T1 (de) Derivate der phosphonsäure, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die sie enthalten
ATE203665T1 (de) Stabilisierte pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung
ATE127465T1 (de) Isoindolinon-derivat, seine herstellung und dieses enthaltende pharmazeutische zusammen setzungen.
ES2079521T3 (es) Derivados del n-alfa-fluor-acriloilaminoacido, opticamente activos, su obtencion, los polimeros opticamente activos obtenidos a partir de ellos y su uso para la separacion de racematos.
ATE160938T1 (de) Feste orale pharmazeutische zubereitung mit gemfibrozil als aktiver inhaltsstoff und verfahren zur herstellung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties